News & Presentations

Generation of synthetic cytokine receptor-induced cytotoxic innate lymphocytes (iCILs) from iPSCs as off-the-shelf cancer therapeutics.
April 10, 2022

1:30 PM - 5:00 PM

More Information>

Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 8, 2022

SEATTLE, April 8, 2022 (GLOBE NEWSWIRE) – Umoja Biopharma, Inc., an oncology company leveraging its proprietary integrated technologies to create next-generation off-the-shelf in vivo (VivoVec) and induced pluripotent stem cell (iPSC) based immunotherapies for the treatment of solid tumors and hematologic malignancies, announced today the presentation of data supporting the use of a synthetic cytokine receptor, the Rapamycin Activated Cytokine Receptor (RACR), to derive synthetic innate lymphoid cells, RACR-induced cytotoxic innate lymphoid cells (RACR-iCILs).

READ MORE >

Synthetic cytokine receptor enables enhanced persistence and next-generation manufacturing of iPSC-derived allogeneic CAR cells
February 24, 2022

9:15am ET

More Information>

A scalable and flexible future for gene therapy production
November 1, 2021

3:00pm ET

More Information>

Umoja Biopharma Appoints Biotech Industry Leader Clay Siegall, Ph.D. as Chairman of the Board
October 15, 2021

Seattle, Wash., October 18, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of Clay Siegall, Ph.D. as its Chairman of the Board of Directors.

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.